Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P27448

UPID:
MARK3_HUMAN

ALTERNATIVE NAMES:
C-TAK1; Cdc25C-associated protein kinase 1; ELKL motif kinase 2; Protein kinase STK10; Ser/Thr protein kinase PAR-1; Serine/threonine-protein kinase p78

ALTERNATIVE UPACC:
P27448; A0A0A0MQR8; A0A0A0MST9; A0A0A0MT23; O60219; Q86TT8; Q8TB41; Q8WX83; Q96RG1; Q9UMY9; Q9UN34

BACKGROUND:
Serine/threonine-protein kinase p78, alternatively known as MAP/microtubule affinity-regulating kinase 3, is crucial for phosphorylating microtubule-associated proteins and regulating cell cycle checkpoints. It modulates the activity of histone deacetylases and the Hippo signaling pathway, affecting cellular proliferation and differentiation. Its kinase activity extends to proteins like PKP2 and KSR1, underscoring its broad role in cellular signaling.

THERAPEUTIC SIGNIFICANCE:
Given its role in a rare, autosomal recessive disease causing visual impairment and progressive phthisis bulbi, MAP/microtubule affinity-regulating kinase 3 represents a promising target for drug discovery. Understanding the role of MAP/microtubule affinity-regulating kinase 3 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.